Inogen, Inc. (INGN)
| Market Cap | 200.56M |
| Revenue (ttm) | 348.67M |
| Net Income (ttm) | -22.75M |
| Shares Out | 27.32M |
| EPS (ttm) | -0.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 527,624 |
| Open | 7.24 |
| Previous Close | 7.25 |
| Day's Range | 7.24 - 7.67 |
| 52-Week Range | 5.34 - 9.13 |
| Beta | 1.71 |
| Analysts | Strong Buy |
| Price Target | 11.25 (+53.27%) |
| Earnings Date | May 7, 2026 |
About INGN
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airw... [Read more]
Financial Performance
In 2025, Inogen's revenue was $348.67 million, an increase of 3.86% compared to the previous year's $335.71 million. Losses were -$22.75 million, -36.62% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for INGN stock is "Strong Buy." The 12-month stock price target is $11.25, which is an increase of 53.27% from the latest price.
News
Inogen to Report First Quarter 2026 Financial Results on May 7, 2026
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report First Quarter 2026 Financial Results on May 7, 2026.
Inogen Transcript: 25th Annual Needham Virtual Healthcare Conference
Leadership expansion and strategic hires support transformation into a broader respiratory care platform. New product launches, including Voxi 5, Simeox, and Aurora masks, are expected to drive growth and margin improvement, while B2B channel gains offset DTC headwinds. Share repurchases and disciplined spending reinforce a focus on shareholder value.
Inogen Announces the Appointment of Vafa Jamali to Board of Directors
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces the Appointment of Vafa Jamali to Board of Directors.
Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference.
Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth.
Inogen Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Management outlined a successful transformation to a diversified portfolio, expanding TAM and returning to profitable growth. New products and international expansion are expected to drive 6% revenue growth in 2026, with a focus on margin improvement and high single-digit growth over the next 3–5 years.
Inogen Announces Participation in the KeyBanc Virtual Life Sciences & MedTech Investor Forum
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Participation in the KeyBanc Virtual Life Sciences & MedTech Investor Forum.
Inogen Earnings Call Transcript: Q4 2025
Delivered 4% revenue growth in 2025, returned to positive adjusted EBITDA, and launched new products expanding the addressable market to $3.4B. Guidance for 2026 targets 6% revenue growth and continued profitability, supported by a $30M share repurchase program.
Inogen Announces Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Outlook
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Outlook.
Inogen Announces $30 Million Share Repurchase Program
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces $30 Million Share Repurchase Program.
Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026.
Inogen Announces the Launch of Aurora CPAP Masks for Obstructive Sleep Apnea in the United States
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces the Launch of Aurora CPAP Masks for Obstructive Sleep Apnea in the United States.
Inogen Earnings Call Transcript: Q3 2025
Q3 2025 saw 4% revenue growth to $92.4M, led by strong international B2B gains and improved profitability. New product launches and disciplined cost management supported a raised full-year adjusted EBITDA outlook, with continued focus on innovation and global expansion.
Inogen Announces Third Quarter 2025 Financial Results
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Third Quarter 2025 Financial Results Delivered seventh consecutive quarter of mid-single-digit revenue growth.
Inogen to Report Third Quarter 2025 Financial Results on November 5, 2025
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today an...
Inogen Announces the Appointment of Naga Rameswamy as Chief Technology Officer
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces the Appointment of Naga Rameswamy as Chief Technology Officer.
Inogen Earnings Call Transcript: Q2 2025
Q2 2025 saw 4% revenue growth to $92.3M, driven by strong B2B channels and a 19% unit volume increase. Gross margin was 44.8%, and adjusted EBITDA reached $2.1M. Full-year guidance was raised, with VOXY-5 and digital health launches expanding the addressable market.
Inogen Announces Second Quarter 2025 Financial Results
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Second Quarter 2025 Financial Results; Delivered strong top-line results; raising full year 2025 revenue expectations.
Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025.
Inogen Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy.
Inogen Upgraded: Analyst Sees Growth, EBITDA Breakthrough
Needham analyst Mike Matson upgraded Inogen, Inc INGN from Hold to Buy, with a price forecast of $12.
Inogen Earnings Call Transcript: Q1 2025
Q1 2025 revenue grew 5.5% year-over-year to $82.3 million, led by strong B2B channel gains, while DTC and rental segments declined but showed signs of stabilization. Adjusted EBITDA turned positive, and full-year guidance was reaffirmed, with no significant tariff impact expected.
Inogen Announces First Quarter 2025 Financial Results
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces First Quarter 2025 Financial Results.
Inogen Transcript: 24th Annual Needham Virtual Healthcare Conference
Leadership restructuring and strategic partnerships have set the stage for growth, with new product launches and a focus on digital health. Expansion into China and the introduction of new devices are expected to drive future profitability, while operational efficiencies and cost controls support improved margins.